CT joins $13.5M multistate settlement with Boehringer Ingelheim

Lester Mason
December 21, 2017

DE joined 49 other states in reaching a settlement with Boehringer Ingelheim Pharmaceuticals, Inc. regarding alleged off-label marketing and misleading promotions of fours of its prescription drugs, including Micardis®, Aggrenox®, Atrovent®, and Combivent®.

Erin Crew, a Boehringer spokeswoman, said the allegations were essentially the same as those that were part of a settlement in 2012 with the federal government and a group of states bringing Medicaid claims.

At issue was Boehringer Ingelheim's marketing of the drugs Micardis, Aggrenox, Atrovent and Combivent. "Everyone deserves to have accurate and medically sound information about the medicines they are prescribed".

Senior Assistant Attorney General Jim Boffetti, who leads New Hampshire's consumer protection unit, says the money the state gets from this settlement will likely go back to funding work on future consumer protection cases.

Schneiderman today announced a $13.5 million agreement with Boehringer Ingelheim Pharmaceuticals, Inc. It ranks as one of the world's 20 leading pharmaceutical companies with roughly 48,000 employees. If approved by the court, Connecticut's share of the settlement funds will be $186,357.19 and will be deposited into the state's general fund. In a statement, the company also noted that the alleged conduct ended in 2008. "We have agreed to the settlement to avoid the costs associated with a further prolonged legal process related to these allegations".

"Resolving this matter allows us to focus our energy and resources on researching and developing innovative products to improve patients' lives", Boehringer said.

The AGs alleged BI claimed the hypertension medication Micardis protected patients from early morning risks of strokes and heart attacks, and treated metabolic syndrome.

The settlement requires the company to make sure its marketing and promotional practices fairly represent its products.

BIPI will limit product samplings of the drugs to health care providers whose clinical practice is consistent with product labeling. The company must also refrain from offering financial incentives for sales that may indicate off-label use of any of the drugs and ensure clinically relevant information is provided in an unbiased manner distinct from promotional materials.

Other reports by Iphone Fresh

Discuss This Article